Pioneering Through Leadership Transition
Altimmune, based in Gaithersburg, Maryland, is entering a pivotal phase. From January 1, 2026, Jerry Durso will step in as the new CEO, succeeding Vipin Garg, Ph.D., who has been at the helm for seven transformative years. This transition comes as Altimmune gears up for late-stage clinical developments, particularly with their promising drug candidate, pemvidutide, aimed at treating liver diseases.
Celebrating Dr. Garg’s Legacy
Dr. Garg’s leadership has been marked by the robust development of pemvidutide from discovery through Phase 2 trials. His vision and strategic direction have significantly strengthened Altimmune’s scientific and financial foundations. As stated in BioBuzz, his continuing advisory role until mid-2026 will support a seamless transition, ensuring continuity and sustained growth.
Jerry Durso Brings Vast Experience
Jerry Durso, familiar with the intricacies of pharmaceutical leadership, brings a wealth of experience from his previous roles at Intercept Pharmaceuticals and Sanofi. Under his guidance, Intercept Pharmaceuticals successfully expanded its reach in the rare disease market before being acquired by Alfasigma. His appointment as Altimmune’s Board Chair earlier this year set the stage for this leadership transition.
Charting New Paths in Biopharma
Expressing enthusiasm at his new role, Durso emphasized the potential of pemvidutide to improve standards of care in liver disease. He plans to build on Altimmune’s solid groundwork, focusing on Phase 3 preparations and the eventual commercialization of its key therapeutic offerings. His tenure promises not just continuity but innovation, ushering the company into its next era.
Reinforcing Maryland’s Biotech Edge
Altimmune’s CEO transition is yet another testament to Maryland’s thriving biotech ecosystem. Jerry Durso’s leadership promises to further embed this region’s reputation as a hub for high-impact therapeutic innovations. With strategic developments on the horizon, Altimmune exemplifies the forward momentum characteristic of Maryland’s biopharma scene.
This transition not only stands as a landmark within Altimmune but also underscores the broader biotech currents shaping the BioHealth Capital Region’s trajectory. The groundwork laid under Dr. Garg’s leadership now sets the stage for new achievements as Jerry Durso takes the helm.
